"CDE grants BTD to Innovent’s IBI343 for pancreatic cancer" was originally created and published by Pharmaceutical Technology ...
ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...
The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...
An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...
Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...
A revolutionary advancement in cancer treatment at UH Seidman Cancer Center is dramatically reducing the time patients spend ...
Hydrogen peroxide creates a toxic environment for cancer cells. The jabs, given directly into the tumour, weaken the cells, ...
The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...
Hosted on MSN6d
Prostate cancer breakthrough: New experimental medicine seen to shrink advanced tumoursA breakthrough experimental drug has shown promising results in shrinking advanced prostate cancer tumours, offering new hope ...
Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...
Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback